NYSE: ARMP - Armata Pharmaceuticals, Inc.

六个月盈利: -17.58%
部门: Healthcare

促销时间表 Armata Pharmaceuticals, Inc.


关于公司

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp.

更多详情
for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

IPO date 2011-03-09
ISIN US04216R1023
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.armatapharma.com
Цена ао 4.04
每日价格变化: +4.46% (2.02)
每周价格变化: +8.21% (1.95)
每月价格变化: -8.26% (2.3)
3个月内价格变化: -10.59% (2.36)
六个月内的价格变化: -17.58% (2.56)
每年价格变化: -34.88% (3.24)
3年内价格变化: -61.71% (5.51)
5年内价格变化: -49.52% (4.18)
10年价格变化: 0% (2.11)
年初以来价格变化: -1.4% (2.14)

低估

姓名 意义 年级
P/S 18.4 1
P/BV -2.6 0
P/E 0 0
EV/EBITDA -4.76 0
全部的: 3.13

效率

姓名 意义 年级
ROA, % -62.79 0
ROE, % 215.33 10
全部的: 3.33

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -2.3 10
全部的: 7.8

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 14509.68 10
盈利能力 Ebitda, % 119.33 10
盈利能力 EPS, % -19.58 0
全部的: 8

ETF 分享, % 本年盈利能力, % 股息, %
iShares Micro-Cap ETF 0.00569 17.09 1.54048



导师 职称 支付 出生年份
Dr. Mina Pastagia M.D., MS Chief Medical Officer 463.75k 1975 (50 年)
Dr. Deborah L. Birx M.D. CEO & Director 536.43k 1957 (68 年)
Dr. Pierre Kyme Ph.D. Chief Business Officer N/A
Mr. Peter Hubbard Vice President of Operations N/A
Mr. David House Senior VP of Finance & Principal Financial Officer

地址: United States, Marina del Rey. CA, 4503 Glencoe Avenue - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.armatapharma.com